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Objectives. Although complete ulcer healing is the mandatory primary efficacy criterion in current European guidelines
for drug trials in critical limb ischemia (CLI), the appropriateness of this endpoint has been questioned for some time. We
carried out a systematic review to assess the value of this endpoint in studies on reconstructive measures, considered to be
the standard of care for CLI.
Methods. A computerized literature search (1985e2005) was performed to track down clinical studies on endovascular
and surgical interventions by using the search terms CLI and ulcer healing and their synonyms.
Results. 1,914 papers on revascularization in CLI were identified. Complete ulcer healing was reported in 17 studies
(0.9%). Among these, there were no randomized controlled trials, five prospective cohorts on endovascular procedures,
and six retrospective cohorts for endovascular and surgical procedures, respectively. If healing rates or time to ulcer healing
were available, they differed greatly between the studies without consistent correlation to types of therapy.
Conclusions. In past and current literature, complete ulcer healing is not a consistently reported criterion for success of
revascularization in CLI. Thus, its appropriateness for efficacy assessment of drug studies in CLI patients has to be
questioned.
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The European Committee for Proprietary Medicinal
Products (CPMP) guidelines provide thorough meth-
odological criteria for the conduct of confirmatory clin-
ical drug trials. They are well accepted and form the
basis for creating evidence in current medicine. For
drug trials in patients with critical limb ischemia
(CLI), the CPMP guidelines demand complete ulcer
healing as the primary efficacy criterion.1 The appro-
priateness of complete ulcer healing as the sole
primary efficacy parameter for drug trials in CLI has
been questioned,2 since clinically important aspects
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or the functional status of the patient are not consid-
ered. Notably, currently licensed and accepted drugs
for CLI have been tested using a combined clinical
endpoint consisting of partial and complete ulcer
healing.3e9 Thus, the demand for complete ulcer heal-
ing as the sole primary efficacy parameter for confir-
matory trials poses substantial difficulties to the
assessment of already approved drugs and the imple-
mentation of future drug trials in CLI patients.
Surgical or endovascular revascularization is re-
garded as the standard of care for treating CLI pa-
tients. Hence, it is of interest to analyse whether and
to what extent complete ulcer healing is used as a pri-
mary efficacy parameter in studies on reconstructive
measures. We have therefore performed a systematic
review of the literature (i) to provide information on
to what degree complete ulcer healing is used as an
312 U. Hoffmann et al.efficacy parameter in studies on endovascular or
surgical interventions (ii) to evaluate the figures for
complete healing rates and healing times in revascu-
larization studies, and (iii) to discuss whether in the
view of the results presented, complete ulcer healing
may be considered appropriate as a sole primary end-
point for efficacy in CLI drug studies.
Methods
Search strategy
Computerized searches of the English and German
medical literature from January 1985 to December
2005 were performed on Medline, BIOSIS, EMBASE
and SciSearch. In addition, reference lists of retrieved
articles were evaluated to identify relevant publica-
tions that might have been missed in the electronic da-
tabase searches. Search terms were looked for in the
title, abstract and keywords fields. To find out specifi-
cally how many of all revascularization studies focus
on ulcer healing, first all studies dealing with endovas-
cular and surgical interventions in CLI were identified,
followed by scanning them for the term ulcer healing.
Apart from the search terms CLI and ulcer, common
synonyms of these terms were also employed: critical
limb isch(a)emia, critical leg isch(a)emia, chronic critical
leg isch(a)emia, end-stage isch(a)emia, limb-threatening is-
ch(a)emia, isch(a)emia of the lower limb, lower limb isch(a)e-
mia, Fontaine stage IV, PAOD, PAD, peripheral (arterial)
occlusive disease stage IV, POAD, peripheral occlusive arte-
rial disease, PVD, peripheral vascular disease; isch(a)emic
ulcer, lower extremity ulcer, ulceration, isch(a)emic ulcera-
tion, chronic ulceration, ulcer area, isch(a)emic lesion, tro-
phic lesion, chronic wound, gangrene, tissue loss.
Selection criteria
Reviews, case reports and studies with less than 10
patients were not eligible. Studies were selected for
analysis if they fulfilled the following criteria: Ulcers
had to be of ischemic origin, hence studies with neu-
ropathic, postoperative, mixed arterial/venous, and
pressure ulcers were excluded, as were those with
ulcers due to thromboangiitis obliterans. Only studies
applying surgical or interventional therapeutic mea-
sures that are recommended in the relevant guidelines
were taken into account,6e9 which excluded such
measures as spinal cord stimulation or sympathec-
tomy. After checking the publications, just those stud-
ies were selected that presented clear quantitative
data on rates of complete healing and the time needed
for healing.Eur J Vasc Endovasc Surg Vol 33, March 2007Results
The computerized search identified 1914 studies deal-
ing with surgical or endovascular interventions in
CLI. After searching the retrieved articles for the
term ulcer healing and its synonyms, only 88 remained
(Fig. 1). On carefully checking these papers and
applying the inclusion and exclusion criteria men-
tioned above, just 17 studies were considered accept-
able for the present review, namely 6 bypass studies
and 11 studies on endovascular interventions, some
of which were combined with bypass surgery. None
of the 17 studies was randomized or controlled, and
only 5 were prospective. In none of the prospective
studies, however, was complete ulcer healing defined
as the only primary efficacy endpoint. In all studies
and surveys, respectively, ulcer healing was one of
several efficacy parameters such as limb salvage or
patency rates. Nearly all trials included diabetic as
well as non-diabetic patients. A characterisation of
disease severity of PAD at baseline in terms of ankle
pressure, ankle-arm-index or equivalent parameters
(toe pressure, tcPO2, plethysmography) was available
only in two studies.10,11 Only two trials10,12 presented
exact data on healing rates separately for diabetic and
Search Strategy
Medline, BIOSIS, EMBASE, SciSearch
1914 Number of studies on surgical or
endovascular interventions in CLI. 
Elimination of studies dealing with 
amputation (surgical therapy).
1273
Combination with the search term ‘‘ulcer
healing’’ (and its synonyms).
88
Evaluation of titles and abstracts with 
regard to the selection criteria; in case of
potential relevance followed by evaluation 
of the full paper. 
17
Final number of relevant studies 
presenting quantitative data on complete 
healing rate and healing time.
Fig. 1.
313Complete Ulcer Healing in CLI Studiesnon-diabetic patients. Due to the great heterogeneity
of all studies, a pooled analysis of the data was not
possible.
Ulcer healing following vascular surgery
No prospective studies in vascular surgery with data
on complete ulcer healing and healing times were
found. Only 6 retrospective surveys reported on such
data.10,11,13e16 Apart from debridement, an intensive
special wound treatment (e.g. skin grafting, fibroblast-
derived dermal substitute) was utilized in two
studies.13,15 The four remaining studies10,11,14,16 did
not provide any details on local wound treatment.
In all studies minor amputations were performed if
appropriate, to improve wound healing. Moreover,
in two studies14,15 clinical outcome was influenced
by secondary interventions. While exact figures on re-
peat operations (176 interventions in 112 patients)
were given in one of these papers,14 no such data
were given in the other.15 Two studies10,16 evaluated
ulcer healing only in patients with grafts that had
remained patent throughout the entire follow-up.
Healing rates (37e96%), and particularly healing
times (0.4e48 months), differed considerably through-
out the studies with a broad variability of follow-up
ranging from 6 months to 5 years (Table 1).
Ulcer healing following endovascular or combined
endovascular and surgical intervention
Six retrospective surveys12,17e21 and 5 prospective but
uncontrolled studies22e26 on interventional measures(some combined with bypass surgery) were identified
that provided data on complete ulcer healing and
healing times. As with the vascular surgery trials,
healing rates (15e100%) as well as healing times
(1e30 months) showed large variations among the
studies and included almost always minor amputa-
tions as a part of the therapeutic strategy (Table 2).
In four studies the reported healing rates did not re-
late to the entire study population, but only to success-
fully recanalized patients22,24,26 or those for whom
complete follow-up data were available.20 In two
studies12,25 the results of two differently treated patient
groups (PTA and bypass)were evaluated together. One
retrospective survey17 thoroughly investigated wound
healing in 85 patients, among them ‘‘many’’ diabetics
(no figures reported). These patients received compre-
hensive local ulcer management (e.g. topical growth
factors) in a specialized wound care center in addition
to endovascular interventions. In contrast, no details
of local ulcer treatment were given in eight studies.18e25
Secondary interventions were performed in all but
two of the studies.19,25
Discussion
As the present review documents, ulcer healing is
rarely reported as an efficacy parameter in clinical
studies on revascularization therapies in CLI. Less
than 1% of all studies provided data on complete ul-
cer healing and healing times. Most notably, among
these there was no single randomized controlled
study. Methodological quality of the studies was
poor and varied considerably so that none of theTable 1. Studies with complete ulcer healing following vascular surgery
Study Design CLI-patients (n) Healing timea,b Complete ulcer healing including
minor amputation (%)
Reichmann et al., 199015 retrospective 80 (34 diabetics)
(100 revascularizations)
2.2 years (mean)b 68% after 5 years
range: up to 5 years
Nicoloff et al., 199814 retrospective 112 (53 diabetics) 5.2 months (mean)a 76% at last follow-up
range: 0.4e48.3 months
Brochado Neto et al., 200011 retrospective 11 (4 diabetics) 19 months (median)b 64% at last follow-up
range: 6e43 months
McCulloch et al., 200313 retrospective 74 (36 diabetics)
(93 limbs)
6 monthsb 37%
12 monthsb 51%
16 monthsb 66%
Woelfle et al., 200316 retrospective 34 (27 diabetics) 6 monthsb Only 16 patients with patent
grafts after 6 months were
evaluated: 50% (8/16)
Woelfle et al., 200310 retrospective 211 (94 diabetics) 12 monthsb Only 26 resp. 28 patients with
patent grafts after 12 months
were evaluated:
81% (21/26) diabetics
96% (27/28) non-diabetics
a in patients that healed.
b within follow-up.Eur J Vasc Endovasc Surg Vol 33, March 2007
Table 2. Studies with complete ulcer healing following endovascular or combined endovascular and surgical intervention
Study Design CLI-patients (n) Revascularization Healing timea,b Complete ulcer healing including
minor amputation (%)
Only 18 successfully recanalized patients
were evaluated: 31% (5/18)
an)b Results (after 5 months) include
additional bypass surgery because of
restenosis:
(a) 100%
(b) 90%
(c) 72%
orted
edian)a 79% (27/34) of limbs after 7.5 months
(median)onths
data of all patients with different
interventions:
55%
70%
75%
diabetics:
64% of ulcers after 12 months
non-diabetics:
80% of ulcers after 12 months
ean)b 79% after 12 months (mean)
onths
an)a
dian)a 60% of patients within follow-up of
20 months (median);
nths cumulative ulcer healing rates:
3 months: 15%
6 months: 40%
12 months: 54%
24 months: 81%
ean)b Only 21 patients with procedural success
were evaluated: 86% (18/21)onths
onthsb data of all patients with different
interventions: 63% of limbs
ean)a Only 20 patients were followed for
1 year: 55% (11/20)
an)b 33% (4/12) of patients after 3 months
(mean)orted
ean)b Entire cohort (n¼ 32) after 1 year: 70%
months PTA: only 13 patients with successful PTA
were evaluated: 69% (9/13);
Bypass: no clear follow-up data
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ascWhite et al., 199022 prospective not
randomised
uncontrolled
27 (17 diabetics) laser angioplasty 6e24 monthsa
Crew et al., 199417 retrospective 85 (‘‘many’’ diabetics)
(96 limbs)
(a) iliac stent (7 limbs) 5 months (me
(b) PTA femoropopliteal
(42 limbs)
range: not rep
(c) rotational atherectomy
tibioperoneal (47 limbs)
plus comprehensive
wound management in
a specialized wound care
center
London et al., 199518 retrospective 53 (26 diabetics) (34
with ulcers)
PTA iliacal,
femoropopliteal,
infrapopliteal
7.5 months (m
range: 3e18 m
Konradsen et al., 199612 retrospective 39 (15 diabetics)
(42 ulcers)
6 monthsb
9 PTA 12 monthsb
33 bypass 18 monthsb
Hanna et al., 199723 prospective not
randomised
uncontrolled
29 diabetics PTA infrapopliteal
(in 2 patients rotational
atherectomy)
12 months (m
range: 1e30 m
3 months (me
Mlekusch et al., 200219 retrospective 40 (32 diabetics) PTA femoropopliteal 5 months (me
range: 2e7 mo
Boccalandro et al., 200424 prospective not
randomised uncontrolled
25 (20 diabetics) laser angioplasty 13 months (m
range: 5e25 m
Losa et al., 200425 prospective not
randomised uncontrolled
50 diabetics (59 limbs) 38 PTA endpoint: 15 m
20 bypass
Atar et al., 200520 retrospective 38 (27 diabetics)
(31 with ulcers)
PTA popliteal,
infrapopliteal
4.5 months (m
12 monthsb
Clair et al., 200521 retrospective 19 (11 diabetics)
(13 with ulcers)
PTA femoropopliteal 3 months (me
range: not rep
Jacqueminet et al., 200526 prospective not
randomised
uncontrolled
32 diabetics 25 primary PTA
6 primary bypass
36 secondary bypass
after unsuccessful PTA
8.5 months (m
range: 1.5e24
a in patients that healed.
b within follow-up.
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315Complete Ulcer Healing in CLI Studiesreports would have met the CPMP criteria currently
required for drug trials in CLI patients.1 Even basic
clinical parameters such as ankle pressures were fre-
quently lacking. Results in diabetics versus non-
diabetics were usually not reported separately nor
were CLI populations stratified for this important
confounder as required by CPMP. Moreover, exact
definitions of the standard of wound management
was the exception and secondary interventions dur-
ing follow-up were not reported consistently.
By analysing the healing rates and healing times,
large variations among the 17 studies selected (12
retrospective surveys, 5 prospective but uncontrolled
and non-randomized trials) were observed. In almost
all studies minor amputations as well as secondary in-
terventions were part of the therapeutic strategy. With
a broad range of the length of follow-up lasting up to 5
years,15 healing times of 0.4 to 48 months and healing
rates ranging from 15% to 100% were reported. Apart
from variability in follow-up the vast differences in ul-
cer healing may be explained by the heterogeneity of
ulcer origin, the degree of soft and bone tissue involve-
ment and the different concepts of local ulcer treat-
ment. In addition, a variety of comorbidities may
have influenced the complex process of wound heal-
ing.27 Drug as well as revascularization trials would ei-
ther require stratification for these multiple variables
or would need rigorous inclusion and exclusion crite-
ria in order to account for this heterogeneity. Whereas
the first strategywill result in unrealistically high num-
bers of CLI patients to be included in a trial the latter
will severely impede recruitment of patients and result
in a highly selected study population.
In planning a confirmatory, randomized, double-
blind and placebo-controlled drug trial in CLI patients
based on the CPMP criteria for the proof of efficacy, it
is necessary to have an estimate on the time and the
percentage of complete ulcer healing for the drug as
well as for placebo. Thus, studies on revascularization
procedures which are considered the standard of care
in CLI do not provide any reliable basis for a point es-
timate. Due to the broad variability of results reported
it appears almost impossible to define the hypothesis
and the necessary sample size for a confirmatory drug
trial using complete ulcer healing as the primary
efficacy criterion. Moreover, data on healing rates for
placebo treatment are also missing.
If one were to insist on the same efficacy criteria for
revascularization therapy as currently required for
drug trials neither surgical nor interventional mea-
sures would be accepted as efficacious in CLI patients.
By contrast, for methodologically sound revasculari-
zation studies in CLI, accepted efficacy criteria seem
to be limb salvage or amputation-free survival; asa technical surrogate parameter graft patency may
be given.8 In the recent BASIL trial,28 such endpoints
served as a basis for meaningful conclusions for the
comparison of bypass surgery versus angioplasty in
CLI patients despite the heterogeneity of the patient
population. Notably, complete ulcer healing was not
even a secondary endpoint in this study. The inconsis-
tency of the sole endpoint ulcer healing in CLI studies
has also been recognized by Rutherford et al. in their
revised version of the ‘‘Recommended Standards for
Reports Dealing with Lower Extremity Ischemia.29’’
In view of the data presented, it appears justified to
critically revise CPMP criteria for confirmatory drug
trials. The definition of new endpoints for assessing
the efficacy of therapeutic measures in CLI studies
should be both clinically relevant and realistic, and
should equally apply to pharmacotherapy and revas-
cularization procedures. Thus, more appropriate
alternative endpoints may include amputation-free
survival, the functional status of the patient, and qual-
ity of life. Composite or response-based endpoints
considering also the time to and duration of response
have already been proposed by the Basel I conference1
and may form the basis for future discussions.
References
1 European Agency for the Evaluation of Medicinal Products,
CPMP/EWP/714/98 rev 1. Note for guidance on clinical inves-
tigation of medicinal products for the treatment of peripheral
arterial occlusive disease.
2 LABS KH, DORMANDY JA, JAEGER KA, STUERZEBECHER CS, HIATT WR,
on behalf of the Basel PAOD Clinical Trial Methodology Group.
Trans-atlantic conference on clinical trial guidelines in PAOD
(peripheral arterial occlusive disease) clinical trial methodology.
Eur J Vasc Endovasc Surg 1999;18:253e265.
3 CREUTZIG A, LEHMACHER W, ELZE M. Meta-analysis of randomised
controlled prostaglandin E1 studies in peripheral arterial occlu-
sive disease stages III and IV. VASA 2004;33:137e144.
4 LOOSEMORE TM, CHALMERS TC, DORMANDY JA. A meta-analysis of
randomized placebo control trials in Fontaine stages III and IV
peripheral occlusive arterial disease. Int Angiol 1994;13:133e142.
5 CREUTZIG A, DIEHM C, HEIDRICH H, THEISS W. Chronische periphere
arterielle Verschlußkrankheit. In: CLASSEN M, DIERKESMANN R,
HEIMPEL H et al, eds. Rationelle Diagnostik und Therapie in der
Inneren Medizin. Mu¨nchen: Urban & Fischer; 2003.
6 European Working Group on Critical Leg Ischemia. Second
European consensus document on chronic critical leg ischemia.
Circulation 1991;84(4 Suppl.):1e26.
7 TASC Working Group. Management of peripheral arterial
disease (PAD). TransAtlantic Inter-Society Consensus (TASC).
Int Angiol 2000;19(1 Suppl. 1):1e304.
8 HIRSCH AT, HASKAL ZJ, HERTZER NR, BAKAL CW, CREAGER MA,
HALPERIN JL et al. ACC/AHA guidelines for the management
of patients with peripheral arterial disease (lower extremity,
renal, mesenteric, and abdominal aortic). http://www.acc.org/
clinical/guidelines/pad/index.pdf.
9 ZEHLE A. Stenosen und Verschlu¨sse der Unterschenkelarterien.
In: Vorstand der Deutschen Gesellschaft fu¨r Gefa¨ßchirurgie,
ed. Leitlinien zur Diagnostik und Therapie in der Gefa¨ßchirurgie.
Ko¨ln: Deutscher A¨rzte-Verlag; 1998:59e64.Eur J Vasc Endovasc Surg Vol 33, March 2007
316 U. Hoffmann et al.10 WOELFLE KD, BRUIJNEN H, LOEPRECHT H, RUEMENAPF G,
SCHWEIGER H, GRABITZ K et al. Graft patency and clinical outcome
of femorodistal arterial reconstruction in diabetic and non-
diabetic patients: results of a multicentre comparative analysis.
Eur J Vasc Endovasc Surg 2003;25:229e234.
11 BROCHADO NETO FC, GONZALEZ J, CINELLI Jr M, ALBERS M. Bypass to
the genicular arteries for revascularisation of the lower limb. Eur
J Vasc Endovasc Surg 2000;20:545e549.
12 KONRADSEN L, WOUNLUND J, HOLSTEIN P. Chronic critical leg
ischaemia must include leg ulcers. Eur J Vasc Endovasc Surg
1996;11:74e77.
13 MCCULLOCH SV, MARSTON WA, FARBER MA, FULTON JJ, KEAGY BA.
Healing potential of lower-extremity ulcers in patients with arte-
rial insufficiency with and without revascularixation. Wounds
2003;15(12):390e394.
14 NICOLOFF AD, TAYLOR LM, MCLAFFERTY RB, MONETA GL,
PORTER JM. Patient recovery after infrainguinal bypass grafting
for limb salvage. Vasc Surg 1998;27:256e266.
15 REICHMANNW, NICHOLS B, TONER J, JENVEY W, SOBEL M. Strategies in
the treatment ofmajor tissue loss and gangrene: results of 100 con-
secutive vascular reconstructions. Ann Vasc Surg 1990;4:233e237.
16 WOELFLE K, SCHAAL J, RITTLER S, BRUIJNEN H, LOEPRECHT H. Infrain-
guinale Bypassoperationen bei Patienten mit terminaler Niere-
ninsuffizienz und kritischer Beinischa¨mie: Lohnt sich der
Aufwand? Zentralbl Chir 2003;128:709e714.
17 CREW JR, THUENER M. Wound healing: an endpoint for complex
peripheral angioplasty. J Endovasc Surg 1994;1:88e91.
18 LONDON NJM, VARTY K, SAYERS RD, THOMPSON MM, BELL PR,
BOLIA A. Percutaneous transluminal angioplasty for lower-limb
critical ischaemia. Br J Surg 1995;82:1232e1235.
19 MLEKUSCH W, SCHILLINGER M, SABETI S, MACA T, AHMADI R,
MINAR E. Clinical outcome and prognostic factors for ischaemic
ulcers treated with PTA in lower limbs. Eur J Vasc Endovasc
Surg 2002;24:176e181.
20 ATAR E, SIEGEL Y, AVRAHAMI R, BARTAL G, BACHAR GN, BELENKY A.
Balloon angioplasty of popliteal and crural arteries in elderlyEur J Vasc Endovasc Surg Vol 33, March 2007with critical chronic limb ischemia. Eur J Radiol 2005;53:
287e292.
21 CLAIR DG, DAYAL R, FARIES PL, BERNHEIM J, NOWYGROD R, LANTIS JC
et al. Tibial angioplasty as an alternative strategy in patients with
limb-threatening ischemia. Ann Vasc Surg 2005;19:63e68.
22 WHITE AR, WHITE GH, MEHRINGER MC, CHAING FL, WILSON SE. A
clinical trial of laser thermal angioplasty in patients with ad-
vanced peripheral vascular disease. Ann Surg 1990;212:257e265.
23 HANNA GP, FUJISE K, KJELLGREN O, FELD S, FIFE C, SCHROTH G et al.
Infrapopliteal transcatheter interventions for limb salvage in
diabetic patients: importance of aggressive interventional
approach and role of transcutaneous oximetry. J Am Coll Cardiol
1997;30:664e669.
24 BOCCALANDRO F, MUENCH A, SDRINGOLA S, ROSALES OR. Wireless
laser-assisted angioplasty of the superficial femoral artery in pa-
tients with critical limb ischemia who have failed conventional
percutaneous revascularization. Catheter Cardiovasc Interv 2004;
63:7e12.
25 LOSA S, RUSCAZIO A, FAGLIA E, MANTERO M, GABRIELLI L. Endo-
vascular and surgical treatment of chronic limb ischaemia in
diabetics. J Vasc Endovasc Surg 2004;11:35e39.
26 JACQUEMINET S, HARTEMANN-HEURTIER A, IZZILLO R, CLUZEL P,
GOLMARD JL, HA VAN G et al. Percutaneous transluminal angio-
plasty in severe diabetic foot ischemia: outcomes and prognostic
factors. Diabetes Metab 2005;31:370e375.
27 HUNT TK, HOPF H, HUSSAIN Z. Physiology of wound healing.
Adv Skin Wound Care 2000 May-Jun;13(2 Suppl.):6e11.
28 BASIL trial participants. Bypass versus angioplasty in severe is-
chaemia of the leg (BASIL): multicentre, randomised controlled
trial. Lancet 2005;366:1925e1934.
29 RUTHERFORDRB, BAKER JD, ERNSTC, JOHNSTONKW,PORTER JM,AHNS
et al. Recommended standards for reports dealing with lower ex-
tremity ischemia: revised version. J Vasc Surg 1997;26:517e538.
Accepted 2 October 2006
Available online 14 November 2006
